EGFR and non-small cell lung carcinoma: Our team is now conducting a multicenter, phase III RCT clinical trial in EGFR-mutant NSCLC patients with pathogenic concurrent mutations, comparing anlotinib combined with icotinib vs. icotinib (NCT04797806).